This brand name is authorized in France
The drug ALEPSAL contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Phenobarbital
UNII YQE403BP4D - PHENOBARBITAL
|
|
Phenobarbital has sedative effects and has some protective action against all varieties of human partial and generalised epilepsy, with the exception of absence seizures. Phenobarbital is also effective in preventing seizures in the corresponding experimental animal models of epilepsy. |
|
2
Caffeine
UNII 3G6A5W338E - CAFFEINE
|
|
Caffeine is structurally related to the methylxanthines theophylline and theobromine. Caffeine’s main action is as a CNS stimulant. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AA02 | Phenobarbital | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AA Barbiturates and derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 60622868, 63131269, 66014762, 66086808 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
